News Release

August 22, 2024
JCR Pharmaceuticals Co., Ltd.

Translation

Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation

August 22, 2024 – JCR Pharmaceuticals Co., Ltd. (TSE 4552: Chairman and President Shin Ashida, "JCR") announces the completion today of payment procedures for the disposition of treasury stock as restricted stock compensation, in accordance with the resolution at the meeting of the Board of Directors on July 23, 2024. For more details, please refer to the "Notice Regarding the Disposition of Treasury Stock as Restricted Stock Compensation" on July 23, 2024.

Overview of the Disposition of Treasury Stock

(1)	Type and Number of Shares to be Disposed of	663,500 shares of JCR's common stock
(2)	Disposition Price	625 yen per share
(3)	Total Disposition Amount	414,687,500 yen
(4)	Recipients of Disposition, Number of Recipients and the Number of Shares to be Disposed of	Directors of JCR 10 individuals, 472,000 shares Executive officers who do not concurrently serve as directors of JCR 5 individuals, 118,500 shares Employees of JCR 3 individuals, 24,000 shares Directors of JCR's subsidiaries (concurrent) 2 individuals, 49,000 shares
(5)	Disposition Date	August 22, 2024

About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability,

confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Contact:
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com

###